Navigation Links
BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
Date:2/26/2008

cal industries throughout the research, clinical trial and commercialization phases of drug development. The company offers secure, temperature-controlled storage; real-time tracking of stored biological samples; and next-day return of biomaterials. BioStorage Technologies is privately-held and headquartered in Indianapolis with an additional full- service site near Frankfurt, Germany. For more information about the company, please visit http://www.biostorage.com or call +1 (866) 697-2675 or +49 615 582 4490.


'/>"/>
SOURCE BioStorage Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioStorage Technologies Appoints Lori Ball as Vice President
2. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
3. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
4. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
5. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. NASA MidSTAR-1 successful technologies may be revolutionary
8. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
9. Neurobiological Technologies Sets Date for Research and Development Day
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
11. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... PHOENIX, AZ (PRWEB) April 16, 2015 ... and makes it easier for research institutions to learn ... collect clinical data. , The timing is ideal since ... on Tuesday. Research Kit is an open-source framework for ... 9. It provides a way for researchers to collect ...
(Date:4/16/2015)... DIEGO , April 16, 2015 Avelas ... dedicated to improving cancer surgeries, announced today that it ... fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent ... the company also welcomed the addition of Steven ... The open label, dose escalation study will ...
(Date:4/16/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company ... new orphan drug indications, today announced that the ... a clinical trial site for the ongoing, multicenter Phase ... multiforme (GBM), the most common and deadly form of ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... - The University of Wisconsin Medical Foundation ... the Medical Foundation's clinical data and to improve the ... has choosen QDX Platform V Integration Services from ... company based in Englewood, Colorado. , ,The Medical Foundations ...
... Inc. , a provider of single-molecule DNA analysis technology, announced ... deadly type of brain tumor, known as oligodendroglioma. OpGen, based ... Center and professor of genetics and chemistry at the ... Schwartz . , ,Optical mapping, invented by Schwartz, will enable ...
... A few weeks ago, I referred to offshore outsourcing ... rapidly becoming an issue de lannee (an election year ... and increasing questions about the economic future of the ... spectrum from the contenders for the Democratic presidential nomination ...
Cached Biology Technology:UW Medical Foundation Integrates Medical Records 2OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment 2The Great Offshore Outsourcing Debate 2
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... issue of Proceedings of the National Academy ... mathematical models to analyze huge amounts of data ... in different ocean habitats and metabolic activity in ... in unprecedented detail how environment influences molecular changes ...
... State University process to pretreat corn-crop waste before ... to be added, cutting the cost of making ... expansion) pretreatment process, developed by Bruce Dale, University ... uses ammonia to make the breakdown of cellulose ...
... According to Professor Demain, the petroleum-based economy in the ... lifecycle. Global oil reserves and new petroleum discoveries will ... It is therefore essential to anticipate and avoid any ... new bioenergy alternatives for the marketplace. In the ...
Cached Biology News:Mixing genomics and geography yields insights into life and environment 2Process can cut the cost of making cellulosic biofuels 2
WIF-1 (N-20)...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
...
Biology Products: